DoW Prostate Cancer, Idea Development Award | HT942526PCRPIDA

FY26 Prostate Cancer Research Program (PCRP) Idea Development Award (IDA) - FAQs

What is the FY26 PCRP Idea Development Award (IDA)?

The FY26 Prostate Cancer Research Program (PCRP) Idea Development Award (IDA) is a U.S. Department of Defense grant opportunity intended to fund innovative, early-stage prostate cancer research concepts that could meaningfully advance the PCRP mission. The program emphasis is on new ideas and creative approaches rather than incremental extensions of well-established projects.

Who is offering and administering this funding opportunity?

This opportunity is offered under the Congressionally Directed Medical Research Programs (CDMRP) framework and is administered through the Defense Health Agency Contracting Activity (DHACA).

What is the Funding Opportunity Number for this award?

The Funding Opportunity Number is HT942526PCRPIDA.

When was this funding opportunity created?

The opportunity was created on May 21, 2026.

What is the application deadline?

The application deadline is September 2, 2026.

How many awards does the program expect to make?

The program anticipates making approximately 8 awards.

What type of research is this award intended to support?

This award is designed to support innovative, early-stage prostate cancer research concepts. The core intent is to help launch new ideas and creative approaches, not to fund incremental extensions of well-established projects.

Is there a required programmatic focus or priority area for proposals?

Yes. Every proposed project must directly address one of the FY26 PCRP Overarching Challenges. Applicants must clearly align their research question, aims, and expected impact with the specific challenge area(s) identified for FY26.

What does it mean to "directly address" an FY26 PCRP Overarching Challenge?

Based on the opportunity description, it means the proposal should clearly show how the research question, specific aims, and expected impact align with one or more of the FY26 PCRP Overarching Challenges identified by the program for that fiscal year.

Is this a discretionary grant, and what category does it fall under?

Yes. It is offered as a discretionary research grant in the Science and Technology / R&D category.

What is the CFDA number associated with this opportunity?

The opportunity is listed under CFDA 12.420.

Who is eligible to apply?

Eligibility is listed as unrestricted. This generally indicates that a broad range of applicant organizations may apply, subject to the program rules and federal grant requirements described in the full announcement.

Does this opportunity include a New Investigator option?

Yes. A notable feature of the FY26 IDA is a dedicated New Investigator Category, and the program is explicitly encouraging submissions from early-career researchers.

How does the program define a "New Investigator" for this opportunity?

For this opportunity, a New Investigator is defined as a researcher within 10 years of completing their terminal degree.

Are collaborators required for New Investigator applications?

Yes. Applicants in the New Investigator Category must include collaborator(s) who have established experience in prostate cancer research.

Why does the New Investigator Category require experienced collaborators?

The stated purpose is to strengthen feasibility and ensure appropriate disease-area expertise, supporting strong study design, execution, and interpretation while allowing newer investigators to bring fresh ideas to the field.

Is the award budget ceiling provided?

No. The award ceiling is not specified in the provided source information. Applicants would need to consult the full funding announcement or related CDMRP materials for budget limits.

Where can applicants find details such as allowable costs, project period length, and review criteria?

The provided information notes that applicants should consult the full funding announcement or related CDMRP materials for budget limits, allowable costs, project period length, review criteria, and any additional submission requirements.

Where is the public preannouncement information posted?

Further public information is referenced through the CDMRP preannouncement page at: https://cdmrp.health.mil/pubs/press/2026/pcrppreann.